{"entity":{"id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Ensem Therapeutics, now recruiting.","summary":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06993844 by Ensem Therapeutics, with 233 participants planned, started 2025-06-10 and due to reach its primary completion in 2027-06-30. Interventions recorded: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant and ETX-636 dose expansion in combination with fulvestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06993844","url":"https://clinicaltrials.gov/study/NCT06993844"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06993844","phase":"1/2","setting":"A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors","sponsor":"Ensem Therapeutics","enrolled":233,"outcomes":[]},"route":"/trials/nct06993844/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}]}}